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Despite some risks of a seasonal nature, we opted to locate the
ISN Forefronts Symposium on Molecular and Cellular Mecha-
nisms of Renin-Angiotensin Synthesis and Release in the 'Far
North of Australia' (Port Douglas, Queensland), which was held
on March 27—30, 1993. We were surrounded by tropical rainforest
containing exotic native birds, fauna and flora which embrace one
of the wonders of the world: The Great Barrier Reef. The
advantage of this idyllic location was that registrants were iso-
lated, but there was a slight disadvantage in that travel arrange-
ments were complex. Because the Forefronts meeting was fortu-
itously held immediately after the 15th International Society of
Hypertension meeting, our registrants and key speakers were able
to save significantly on travel expenditures to attend.
To understand the raison d'etre for this Forefronts meeting, one
must ask if we really know how the incredibly therapeutic ACE
inhibitors work effectively. The answer is no: We must ponder how
they work. By our criteria, we believe this meeting was a great
success. The work presented was current, the discussions were
critical and robust, but all was in the spirit of scientific inquiry and
good will.
In this Symposium issue Michael McKinley focuses our atten-
tion on the roles of angiotensin II in the central nervous system,
from its classical role in drinking and thirst to its importance in
blood pressure regulation and regulation of renin secretion and
release. The primacy of central regulation over local changes
needs much further investigation. Professor Mendelsohn's paper
elegantly demonstrates that endogenously produced angiotensin
II can interfere in vivo with access to receptors by agonists and
inhibitors, a very important consideration when interpreting in
vivo experiments.
Dr. de Gasparo's scholarly review of the angiotensin receptor
field sets the stage for several papers which polish our knowledge
of angiotensin II receptors. AT2 receptors overlap in terms of
distribution; they are not internalized and seem to be quite
separate in terms of their lack of recognized function, which
remains an enigma. AT2 receptor(s) may act by inhibiting phos-
photyrosine phosphatase.
Despite our detailed knowledge of angiotensin II receptors, the
difference between AT1 receptors which differentiate between the
potency of angiotensin II and III on the one hand (for example,
smooth muscle), and those which do not (for example, adrenal)
has not been resolved by the AT1A/AT1B classification. Harding's
persuasive studies on the AT4 receptor await further elucidation
of another agonist(s). The key question is whether or not the
hexapeptide A1-6 is the true agonist. Is it locally produced by C
terminal peptidases? Is C terminal metabolism a major route in
the fate of angiotensin II?
Analyses of the upstream regulation of the renin gene are
providing valuable insight into the control of this gene expression.
However, it is too soon to determine the role of renin expression
in the cellular mechanisms which cause production of angiotensin
II, particularly in the central nervous system, and the role of renal
renin gene expression in the replacement of secretory granules in
the kidney and the mechanisms of the response to sodium
depletion or angiotensin II inhibition. In fact, processing secretion
and storage are arenas where much needs to be done, which is
illuminated in the paper by Reudelhuber. Dr. Takahashi reviews
ten years of work on the specific high-affinity renin binding
protein. The renin binding protein joins others with a leucine
zipper motif.
Despite great advances in these areas, a constellation of
questions spring to mind. What regulates processing enzymes? Is
the renin secretory process the same as most other secreted
proteins? What is the role of such a high-affinity specific binding
protein? Is renin taken back up at renal and other sites? The renin
binding protein is not confined to the kidney.
A particular focus of studies about the renin-angiotensin system in
the molecular idiom is the place of transgenic animals, where either
programmed oversecretion is a goal, or gene knockout where a gene
in a homologous strain is deleted. The literature abounds with
examples where application of this complex technology has been
extremely valuable. Far too many examples also exist where only a
very sophisticated model of infusion at a high level is achieved, or
where complex mechanisms to activate the transgene have operated
poorly. Obviously, cross species transgenes may provide a useful
hypertensive model. The fascinating work of Caroline Whitworth
might be further enhanced by concurrent studies of sodium status.
In the crossover renal transplantation experiment of Dr. Rettig or
in the renal clip experiments of Dr. Kurtz, despite the complexity of
the designs, local production of renin and its influence on angiotensin
II concentration and receptor numbers are highlighted, as well as the
importance of the preprogrammed phenotype.
The literature relating to these issues originates with the earliest
studies of Goldblatt in 1934. The subject is complex, ambiguous and
fraught with design and interpretive differences. Nonetheless, as "old
men of the tribe" we feel that close scrutiny of the early studies are
worthwhile and can be very rewarding.
The series of papers on the angiotensinogen gene remind us of
the multi-factorial nature of this interesting system, and again
emphasizes that, while much is known a great deal awaits discov-
ery. For example, the circulating level of angiotensinogen is highly
regulated, but knowledge of how this is influenced, especially by
sodium status, is scarce.
Dr. Phillips opens the door to antisense oligonucleotides as a
new type of pharmacological inhibitor. Despite hypothetical con-
cerns, these oligonucleotides seem to be extremely useful tools.
There are now many cases of the successful use of antisense oligos
in the literature.
The large number of meetings focusing on human hypertension
and its treatment attest to the seriousness of the disease, the
therapeutic complexity, and the enormous investment of the
pharmaceutical industry. Because genes associated with the renin-
angiotensin system have been recently shown to be associated with
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hypertension and coronary heart disease, public health issues
should loom larger in future research.
A variant of the angiotensin converting enzyme gene was found
to be more frequent in cases of myocardial infarction, and the
angiotensinogen gene appears to be linked to hypertension. Dr.
Williams describes his studies as "complementary to physiolo-
genic analysis are genetic approaches, which are designed to
identify mutations in genes which contribute to hypertension. A
particularly useful approach is to determine intermediate pheno-
types in essential hypertension and thus perform linkage analysis
with candidate genes." Harrap reflects on two other approaches:
the affected relative pairs method and four corners methodology.
The Gordon group re-evaluates the incidence of primary aldoste-
ronism in a highly selected cohort of patients and has a revealing
analysis of tumor type. Each study illuminates an aspect of the
renin-angiotensin system that is a departure from normal.
The organizers of this Forefronts Symposium acknowledge the
fact that the meeting relied heavily on the trust of the ISN, and in
particular Professors Gerhard Giebisch and Klaus Thurau, to
enable us to hold it in a site remote from Europe or the United
States. We thank them for their confidence. Thanks also to Dr.
Ian Darby, Dr. Ross Fernley, and Mrs. Lynn Turner for their
efforts in organizing the conference. We greatly appreciate that
Professor Giebisch attended the meeting, and we thank him for
his generous remarks in his formal closure. In addition to the
sponsorship of the International Society of Nephrology, this
Forefronts in Nephrology meeting was supported by the AMRAD
Corporation and the Howard Florey Institute of Experimental
Physiology and Medicine. The Howard Florey Institute is sup-
ported by a block grant from the National Health and Medical
Research Council of Australia and by generous support from
private industry.
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